🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 18 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 25/04/2001 | 37,57 | 39,82 | 36,00 | 38,75 | +5,18% | 10,17% | 1.221.600 |
| 24/04/2001 | 39,89 | 41,39 | 36,26 | 36,84 | -6,71% | 12,86% | 930.200 |
| 23/04/2001 | 41,62 | 41,65 | 38,95 | 39,49 | -5,37% | 6,49% | 531.800 |
| 20/04/2001 | 44,61 | 44,71 | 41,24 | 41,73 | -6,64% | 7,78% | 837.000 |
| 19/04/2001 | 44,57 | 45,81 | 43,04 | 44,70 | -0,64% | 6,21% | 804.600 |
| 18/04/2001 | 43,56 | 46,00 | 42,62 | 44,99 | +6,74% | 7,76% | 1.447.000 |
| 17/04/2001 | 39,00 | 42,63 | 38,02 | 42,15 | +5,82% | 11,82% | 668.900 |
| 16/04/2001 | 43,35 | 43,60 | 39,82 | 39,83 | -8,67% | 8,72% | 978.900 |
| 12/04/2001 | 39,98 | 43,97 | 38,98 | 43,61 | +10,35% | 12,48% | 447.600 |
| 11/04/2001 | 41,38 | 42,05 | 38,80 | 39,52 | -2,40% | 7,85% | 1.051.000 |
| 10/04/2001 | 37,73 | 40,70 | 37,72 | 40,49 | +8,55% | 7,90% | 1.093.800 |
| 09/04/2001 | 36,00 | 37,73 | 35,62 | 37,30 | +4,15% | 5,86% | 498.100 |
| 06/04/2001 | 34,81 | 37,75 | 33,25 | 35,81 | +1,78% | 12,93% | 917.100 |
| 05/04/2001 | 32,31 | 35,75 | 31,88 | 35,19 | +13,51% | 11,99% | 1.059.500 |
| 04/04/2001 | 32,00 | 32,94 | 30,00 | 31,00 | -1,78% | 9,18% | 815.400 |
| 03/04/2001 | 31,19 | 33,88 | 29,75 | 31,56 | -5,08% | 13,23% | 1.110.300 |
| 02/04/2001 | 36,69 | 36,88 | 32,06 | 33,25 | -9,22% | 13,12% | 679.900 |
| 30/03/2001 | 36,00 | 38,00 | 35,31 | 36,63 | +5,54% | 7,47% | 936.400 |
| 29/03/2001 | 33,19 | 37,38 | 32,63 | 34,70 | +3,98% | 14,31% | 1.424.300 |
| 28/03/2001 | 33,56 | 34,50 | 32,13 | 33,38 | -3,61% | 7,08% | 439.300 |
| 27/03/2001 | 34,19 | 35,13 | 32,50 | 34,63 | -0,72% | 7,68% | 802.300 |
| 26/03/2001 | 32,63 | 35,80 | 32,13 | 34,88 | +12,05% | 11,25% | 1.355.800 |
| 23/03/2001 | 29,69 | 32,88 | 28,38 | 31,13 | +6,64% | 15,16% | 1.595.300 |
| 22/03/2001 | 29,13 | 29,50 | 25,63 | 29,19 | -2,51% | 13,30% | 2.267.900 |
| 21/03/2001 | 31,50 | 32,13 | 29,25 | 29,94 | -6,63% | 9,13% | 1.529.400 |
| 20/03/2001 | 34,50 | 35,44 | 31,75 | 32,06 | -6,56% | 10,69% | 1.045.700 |
| 19/03/2001 | 31,69 | 34,63 | 31,13 | 34,31 | +8,50% | 11,05% | 1.130.100 |
| 16/03/2001 | 33,56 | 34,50 | 30,88 | 31,63 | -6,30% | 10,80% | 1.180.900 |
| 15/03/2001 | 35,38 | 35,63 | 31,64 | 33,75 | -2,53% | 11,26% | 1.172.600 |
| 14/03/2001 | 31,75 | 36,73 | 31,75 | 34,63 | -3,15% | 15,70% | 957.000 |